Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 4/20 | 0.49 |
| ▸ | CCNC | P24863 | 3/20 | 0.49 |
| ▸ | ABL1 | P00519 | 8/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 2/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 6/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | BCR | P11274 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23068658 | 1.00 | CDK8 (0.49) | CDK8CCNCABL1NTRK1TEK | |
| SCHEMBL23068668 | 0.92 | CDK8 (0.54) | CDK8CCNCABL1NTRK1TEK | |
| SCHEMBL29629216 | 0.92 | CDK8 (0.54) | CDK8CCNCABL1NTRK1TEK | |
| SCHEMBL29629206 | 0.91 | ABL1 (0.47) | CDK8CCNCABL1NTRK1TEK | |
| SCHEMBL22684885 | 0.91 | ABL1 (0.47) | CDK8CCNCABL1NTRK1TEK | |
| SCHEMBL23068625 | 0.90 | CDK8 (0.54) | CDK8CCNCABL1NTRK1TEK | |
| SCHEMBL29629227 | 0.90 | CDK8 (0.54) | CDK8CCNCABL1NTRK1TEK | |
| SCHEMBL23068641 | 0.89 | ABL1 (0.46) | CDK8CCNCABL1NTRK1TEK | |
| SCHEMBL29629194 | 0.89 | ABL1 (0.46) | CDK8CCNCABL1NTRK1TEK | |
| SCHEMBL23068680 | 0.89 | CDK8 (0.60) | CDK8CCNCABL1NTRK1TEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230092876-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-03-23 | — | — | US | disclosed |
| US-11325900-B2 | 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents | AUCENTRA HOLDINGS PTY LTD (AU) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092876-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | CDK8, CDK18, CDK9 | CDK8 1/4885CCNC 38/4885ABL1 268/4885 |
| US-11325900-B2 | 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents | CDK8, CDK18, CDK9 | CDK8 1/4885CCNC 38/4885ABL1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.